News | April 10, 2009

Cypher Sirolimus Stent Outperforms Taxus Liberte, Endeavor on Some Key Measures

The Cordis Cypher Stent

April 10, 2009 - The results of the ZEST randomized controlled trial released at ACC 2009 showed the Cypher Sirolimus-eluting Coronary Stent significantly outperformed the Endeavor and Taxus Liberte in the key clinical outcomes of ischemia-driven target lesion revascularization (TLR) and stent thrombosis through one year.

TLR is the need for another interventional procedure to open a blockage in the previously stented area. The rates of ischemia-driven TLR and target vessel revascularization (TVR) were lowest in the Cypher group compared to the Endeavor arm (TLR=1.4 vs. 4.9 percent; and TVR=1.9 vs. 5.2 percent) and the Taxus Liberte (TLR = 1.4 vs. 7.6 percent; and TVR = 1.9 vs. 7.7 percent.

However, Endeavor faired slightly better than Cypher and Taxus in the study by having the lowest number of deaths or myocardial infarctions at one year, with Endeavor at 5.8 percent compared to Cypher at 7 percent and Taxus at 7.6 percent.

Cordis, the maker of the Cypher, said ZEST is the largest randomized controlled trial comparing three drug-eluting stents. The company said as in previous trials, like SORT OUT III, the Cypher outperformed Endeavor and Taxus Liberte in terms of key clinical outcomes like TLR and TVR.

In terms of the safety parameters, the company said Cypher had a trend for lower MACE (major adverse cardiovascular events, such as death and heart attack and repeat revascularization) rates at one year - the primary endpoint in the study - than the Endeavor (8.3 vs. 10.1 percent, respectively), and significantly lower rates of MACE than the Taxus Liberte (14.2 percent). The Cypher also had significantly lower rates of stent thrombosis at one year compared to the Endeavor (0.0 percent vs. 0.7 percent) and the Taxus Liberte (0.8 percent).

ZEST was a multicenter, randomized trial of 2,640 patients designed to assess the safety and efficacy of the Endeavor as compared to the Cypher and Taxus Liberte in real world patients. Each treatment arm included approximately 880 patients. The trial was supported by research grants from the CardioVascular Research Foundation, Seoul, Korea, the Korean Ministry of Health and Welfare, and Medtronic Vascular.

Medtronic, maker of the Endeavor stent, said at ACC the ZEST study data showed the Endeavor was not inferior to the Cypher and there was no statistically-significant difference between Endeavor and Cypher. The company also said Endeavor was associated with a statistically significant 29 percent reduction in the composite primary endpoint of death, myocardial infarction (MI) and in ischemia-driven TVR, when compared to the Taxus Liberte at one year.

Boston Scientific’s Taxus Liberte is currently the market leader in the U.S., but Medtronic pointed out the trial results show it to be associated with a 25 percent increase in death and MI, and a 32 percent increase in the need for repeat revascularization when compared to the next-generation Endeavor.

For more information: www.cypherstent.com, www.cordis.com, www.medtronic.com, www.bostonscientific.com

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init